Xianwei Dashi Biology Teams Up with Pfizer China to Accelerate the Commercialization Process of Targeted GLP-1

News Report (Reporter Li Jing)

On February 24, Hangzhou Xianweida Biological Technology Co., Ltd. (hereinafter referred to as “Xianweida Bio”) announced a strategic commercial cooperation with Pfizer China regarding the next-generation biased GLP-1 receptor agonist Ecnoglutide injection (English: Ecnoglutide injection, hereinafter referred to as “Ecnoglutide”). According to the agreement, Pfizer will obtain exclusive commercialization rights for this product in mainland China, marking its first step in the strategic layout of the global metabolic field in China; meanwhile, Xianweida Bio will serve as the marketing authorization holder (MAH) for the licensed product, responsible for its development, registration, manufacturing, and supply. Xianweida Bio will be entitled to receive up to $495 million in payments from Pfizer, including upfront payments, registration, and sales milestone payments.

Ecnoglutide is a new generation cAMP-biased GLP-1 receptor agonist independently developed by Xianweida Bio, providing more precise treatment options for patients with type 2 diabetes and long-term weight management. With its unique biased mechanism, Ecnoglutide injection has demonstrated excellent efficacy and safety in multiple clinical studies. In Chinese populations, the adjusted mean weight loss in the placebo-controlled group was 15.1%, with 92.8% of patients achieving clinically meaningful weight loss, and over 80% reaching blood glucose control (HbA1c<7.0%). Ecnoglutide injection was approved by the National Medical Products Administration (NMPA) in January 2026 for the treatment of adult type 2 diabetes, and its application for long-term weight management in adults has been accepted by NMPA.

Dr. Pan Hai, founder and CEO of Xianweida Bio, stated: “Xianweida Bio is committed to reshaping health through science, aiming to meet the urgent health needs in weight management. We believe that Pfizer, as a leading multinational pharmaceutical company, has deep insights and strong execution capabilities in the Chinese market. Through this strategic cooperation with Pfizer China, we look forward to integrating our innovative scientific achievements with Pfizer China’s top-tier commercialization capabilities to jointly advance the commercialization of Ecnoglutide. Both parties will take ‘Year of Weight Management’ as an important opportunity to work together to bring more diverse and high-quality treatment options to patients with obesity and metabolic diseases in China.”

Alexandre de Germay, Chief Business Officer and Executive Vice President of Pfizer International Markets, said: “This cooperation marks another solid and important step forward in Pfizer’s global strategy in the metabolic field and demonstrates our long-term commitment to playing a leading role in the next-generation chronic weight management therapies. Following the recent acquisition of Metsera and the new global exclusive partnership and licensing agreement with Pharmaron, we are very pleased to collaborate with dynamic local innovative companies like Xianweida Bio. Moving forward, we will continue to invest resources in this highly impactful and high-growth potential therapeutic area, aiming to accelerate bringing these important innovative therapies to patients worldwide and meet unmet patient needs.”

Jean-Christophe Pointeau, Senior Vice President and President of Pfizer China, said: “This collaboration with Xianweida Bio is a significant milestone in accelerating Pfizer’s long-term strategic layout in the metabolic field and meeting the growing needs of Chinese patients. Currently, the adult obesity rate in China is 14.1%, closely related to metabolic diseases such as ‘three highs’ (hypertension, hyperglycemia, hyperlipidemia). ‘Healthy weight management’ has been officially incorporated into the Healthy China Initiative, and this cooperation is a concrete practice of Pfizer’s active response to this strategy. We deeply understand the importance of metabolic health for national well-being. We look forward to working with the excellent team at Xianweida Bio to provide more advanced weight management support for Chinese patients.”